Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

H2-antagonists and alcohol. Do they interact?

R Gugler1

  • 1I. Medizinische Klinik, Städtisches Klinikum, Karlsruhe, Germany.

Drug Safety
|April 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Information needs of patients with prostate cancer. Pronounced differences between individuals after diagnosis of localised prostate carcinoma].

Der Urologe. Ausg. A·2011
Same author

[A young diabetic with small-nodule liver cirrhosis, high transferrin saturation and negative HFE test].

Deutsche medizinische Wochenschrift (1946)·2005
Same author

HJV gene mutations in European patients with juvenile hemochromatosis.

Clinical genetics·2005
Same author

[Topic Complex IV: Erosive reflux disease (ERD)].

Zeitschrift fur Gastroenterologie·2005
Same author

[The elderly patient with esophageal and gastric disease].

Praxis·2005
Same author

Interferon alfa2a induction therapy in combination with ribavirin and amantadine for the treatment of naive patients with chronic HCV infection.

Journal of viral hepatitis·2004
Same journal

Implementation Aspects of a Medicines Shortage Policy Tool: Evidence from Australia's Serious Scarcity Substitution Instruments.

Drug safety·2026
Same journal

Availability and Communication of Risk Management Strategies for Pregnancy Category X Medicines across Australian Medicine Information Sources.

Drug safety·2026
Same journal

The Bidirectionality of Lawyer Reporting Bias in Disproportionality Analysis.

Drug safety·2026
Same journal

Safety of Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis: A Longitudinal Analysis.

Drug safety·2026
Same journal

Developing a Hierarchical Algorithm to Identify Pregnancies and Determine Gestational Age from Nationwide Linked Health Data in Taiwan.

Drug safety·2026
Same journal

Safety and Effectiveness of Direct Oral Anticoagulants Versus Low-Molecular-Weight Heparin for Cancer-Associated Thrombosis: A Systematic Review and Meta-analysis.

Drug safety·2026
See all related articles

First-pass metabolism of alcohol in the stomach is debated, with some histamine H2-receptor antagonists affecting blood alcohol levels in specific individuals. The clinical significance of this interaction is minor and requires further research.

Area of Science:

  • Pharmacology
  • Gastroenterology
  • Biochemistry

Background:

  • Alcohol (ethanol) is primarily metabolized in the liver, but gastric first-pass metabolism by alcohol dehydrogenase (ADH) has been reported.
  • Conflicting data exist regarding the extent of gastric alcohol metabolism and its inhibition by histamine H2-receptor antagonists.
  • Gastric ADH activity varies significantly among individuals and is influenced by factors like gender, ethnicity, and health status.

Purpose of the Study:

  • To investigate the existence and significance of first-pass alcohol metabolism in the stomach.
  • To determine the effect of histamine H2-receptor antagonists on gastric alcohol metabolism and subsequent blood alcohol concentrations.
  • To resolve controversies surrounding this interaction through critical analysis of existing studies.

Main Methods:

Related Experiment Videos

  • Review and analysis of existing pharmacokinetic studies involving oral and intravenous alcohol administration.
  • In vitro studies examining the inhibitory effects of various H2-receptor antagonists on gastric ADH activity.
  • Evaluation of study designs, participant characteristics, and alcohol dosage in published research.

Main Results:

  • First-pass metabolism of alcohol in the stomach occurs with small oral doses and high concentrations, particularly in young, male, non-Asian, non-alcoholic individuals after meals.
  • Cimetidine, ranitidine, and nizatidine have shown varying degrees of inhibition of gastric ADH and increased blood alcohol levels, while famotidine and roxatidine did not.
  • Inconsistent findings are attributed to methodological differences, including study design and participant selection (e.g., inclusion of individuals lacking significant gastric ADH).

Conclusions:

  • The clinical significance of H2-receptor antagonist-induced changes in blood alcohol concentration is minor.
  • First-pass metabolism and its inhibition by H2-antagonists are relevant only in specific populations and under particular conditions.
  • Further rigorously designed studies are necessary to fully elucidate the significance and clinical implications of this interaction.